Amyl Therapeutics raises €8.25M Series A to target Alzheimer's
What's the deal? Belgian biotech Amyl Therapeutics has raised €8.25 million in a Series A extension. The Liège-based company is developing a platform aimed at neurodegenerative diseases, including Alzheimer's.
What's the endgame? Amyl Therapeutics is building a therapeutic platform that targets neurodegenerative conditions. The new capital backs that work as the company advances its approach to Alzheimer's.
The signal: At €8.25 million, the round sits in the 28th percentile by amount among comparable deals — a modest raise in a field where drug development is capital-intensive and slow. For a young European biotech tackling one of medicine's hardest targets, securing an extension keeps the platform moving toward the clinic.
Read more: lecho.be
Image credit: Generated with Gemini
